FDA Accepts Supplement Application for Depemokimab by GlaxoSmithKline
The FDA has accepted the supplemental application for BLA761458, a biologic from GlaxoSmithKline.
Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Immunology / IL-5
Company: GSK
Asset: Depemokimab
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
GSK
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for Depemokimab signifies a potential shift in the competitive landscape of IL-5 therapies. This could impact market dynamics and necessitate strategic adjustments from competitors in the immunology sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for the review process and any subsequent approval announcements.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.